Cambridge Growing Life Centre Cambridge
A group of project managers looking at a plan
BioMed Reality
Planning & Development
How we helped
Financial viability Planning consultancy
Get in touch
@ Justin Bainton
Justin Bainton 
01223 326806 Email me About Justin Bainton

Justin is a Partner for the Eastern Region.   He has approximately 19 years of planning experience and specialises in residential, commercial and mixed use planning applications, dealing with a wide range of planning-related work including site appraisals and feasibility studies; applications relating to commercial, education, residential and student schemes; planning and enforcement appeals; S106 negotiation and the discharge of conditions; development plan representations; and providing general planning advice. Justin advises clients from a diverse sector range including private residential and commercial developers (national, regional and local), education institutions, commercial organisations and private landowners. He has experience in both the public and private sector dealing with a range of development schemes.  He is a Member of the Royal Town Planning Institute. 

I can provide advice on:

Carter Jonas’s Cambridge Planning Team assisted Granta Park Estates in securing planning permission from South Cambridgeshire District Council on the 23rd December 2015 for approximately 55,000m2  (592,015 sqft) of new Research and Development buildings.

This included a full application for a R&D building comprising 21,000m2 earmarked for Illumina, a global leader in genomic analysis and diagnostics, which is now under construction. This will provide a new state-of-the-art building located in scientific research park, Granta Park, and will serve as Illumina’s new European Headquarters. Carter Jonas is continuing to assist during the construction phase of the project.

Carter Jonas has continued to support the evolution of the park over the last 18 months and has since obtained planning consent for a new leisure/amenity building and two significant R&D buildings within the Park for incoming tenants Gilead Sciences Inc. and Heptares Therapeutics Ltd with consent being granted in February 2017.